All In Biotech

NDA 020701 · Abbvie

Crinone

Progesterone · Vaginal · Progesterone

Last checked: Nov 19, 2026Latest source record: Sep 29, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Jul 31, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

897

206 Phase 3, 84 recruiting

FAERS reports

20,427

11,188 serious, 490 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 21, 2024.

INDICATIONS AND USAGE Assisted Reproductive Technology Crinone 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology ("ART") treatment for infertile women with progesterone deficiency. Secondary Amenorrhea Crinone 4% is indicated for the treatment of secondary amenorrhea. Crinone 8% is indicated for use in women who have failed to respond to treatment with Crinone 4%.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 31, 1997 Original approval · Type 3 - New Dosage Form Review
2 products under this application
  • CRINONE · PROGESTERONE 4% · GEL, VAGINAL · Discontinued
  • CRINONE · PROGESTERONE 8% · GEL, VAGINAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Progesterone" as an intervention, any sponsor and status, largest first.

All 897 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache1,893
  • off label use1,733
  • drug ineffective1,678
  • fatigue1,598
  • pain1,348
  • nausea1,325
  • exposure during pregnancy945
  • rash932
  • foetal exposure during pregnancy915
  • hypersensitivity823
  • dizziness818
  • maternal exposure during pregnancy807

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004138
2005157
2006146
2007118
2008174
2009241
2010278
2011246
2012393
2013365
2014471
2015836
20161,229
2017993
20181,093
20191,241
20201,288
20211,252
20221,426
20231,606
20241,998
20252,234
20262,504

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Mar 27, 2026

    Crinone, Vaginal Gel, 4% (NDC 0023-6150-04). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Crinone (Progesterone, Micronized)

2024 spending

$55K

Beneficiaries

48

124 claims

Per beneficiary

$1,141

$20.31 per unit

View as table
YearSpending
2020$75,143
2021$79,960
2022$64,615
2023$70,801
2024$54,774

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,179 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.